Adaptive Phage Therapeutics - Crunchbase Company Profile & Funding

Q: Who invested in Adaptive Phage Therapeutics?

Adaptive Phage Therapeutics has 7 investors including AMR Action Fund And Deerfield Capital Management.

Q: How much funding has Adaptive Phage Therapeutics raised to date?

Adaptive Phage Therapeutics has raised obfuscated.

Overview

Adaptive Phage Therapeutics

Total Funding

obfuscation

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Adaptive Phage Therapeutics

CB Rank

42210

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.

Acquired by

BIOMx

Founded

obfuscation

Private

Series B

Bethesda, Maryland, United States

11-50

www.aphage.com

Biotechnology

Health Care

Pharmaceutical

Therapeutics

Funding Rounds

Series B

OBF

obfuscation

Grant

OBF

obfuscation

Series B

OBF

obfuscation

Key People

Greg Merril: Co-Founder & CEO
Past Role: Adaptive Phage Therapeutics, Co-Founder & CEO
Carl Merril: Co-Founder and CSO

Details

Legal Name

Adaptive Phage Therapeutics, Inc

Operating Status

Closed

Company Type

For Profit

Founders

Carl Merril, Greg Merril

About the Company

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria. Its services are provided using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant

bacteria.

Phone Number

2408992532

Predictions & Insights

Growth Insight

See this Growth Insight

Adaptive Phage Therapeutics is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Products & Services

BX004

A phage therapy for cystic fibrosis patients with chronic Pseudomonas aeruginosa respiratory infections, aimed at improving pulmonary function and reducing lung infections.

BX211

A personalized phage treatment for diabetic foot osteomyelitis associated with Staphylococcus aureus, designed to reduce the risk of amputation in diabetic patients.

Research & Development

Adaptive Phage Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B
obfuscated obfuscation	Series B - Adaptive Phage Therapeutics	2	obfuscated obfuscation	AMR Action Fund, Deerfield Capital Management	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	—
AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	—
AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	—
AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	—
AMR Action Fund	Yes	Series B - Adaptive Phage Therapeutics	—